-- Earnings Flash (ALPN) ALPINE IMMUNE SCIENCES Reports Q3 Revenue $8.5M
4:13PM ET 11/10/2021 MT Newswires...
Quotes Snapshot > ALPN
Alpine Immune Sciences Inc ALPN:NASDAQ
Last Price$11.16Cboe Real-Time Last Sale as of 1:55PM ET 12/01/21
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.33(3.05%)
Bid (Size)$11.04 (108)
Ask (Size)$11.27 (100)
Day Low / High$10.81 - 11.51
Volume33.0 K
Read more news Recent News
Insider Buy: Alpine Immune Sciences
9:26AM ET 9/22/2021 MT NewswiresPeter A. Thompson, 10% Owner, Director, on September 17, 2021, executed a purchase for 1,010,637 shares in Alpine Immune Sciences (ALPN) for $9,499,988....
Insider Sell: Alpine Immune Sciences
5:24PM ET 9/21/2021 MT NewswiresJay Venkatesan, 10% Owner, Director, on September 17, 2021, sold 400,000 shares in Alpine Immune Sciences (ALPN) for $3,760,000. Following the Form 4...
Insider Buy: Alpine Immune Sciences
5:24PM ET 9/21/2021 MT NewswiresXiangmin Cui, 10% Owner, Director, on September 17, 2021, executed a purchase for 1,542,553 shares in Alpine Immune Sciences (ALPN) for $14,499,998....
View all Commentary and Analysis
Alpine Immune Sciences (ALPN) Investor Presentation
11:29AM ET 8/12/2021 Seeking AlphaAlpine Immune Sciences, Inc. (ALPN) CEO Mitchell Gold on Q2 2021 Results - Earnings Call Transcript
10:35PM ET 8/10/2021 Seeking AlphaCelldex: Powerful Medicines To Yield Further Upsides
3:15PM ET 7/08/2021 Seeking AlphaTop 2021 Russell Index Rebalancing Stock Selections To Capture Abnormal Returns
6:32PM ET 6/25/2021 Seeking AlphaCompany Profile
Business DescriptionAlpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Its product pipeline includes inflammatory diseases; immuno-oncology; and engineered cellular therapies. The company was founded in March 2007 and is headquartered in Seattle, WA. View company web site for more details
| Address | 188 East Blaine Street Seattle, Washington 98102 |
| Phone | +1.206.788.4545 |
| Number of Employees | 48 |
| Recent SEC Filing | 11/22/2021 424B3 |
| Executive Chairman & Chief Executive Officer | Mitchell H. Gold |
| President & Head-Research & Development | Stanford L. Peng |
| Finance Director | Thaedra Thullberry |
| Chief Financial Officer, Secretary & Senior VP | James Paul Rickey |
Company Highlights
| Price Open | $11.07 |
| Previous Close | $10.83 |
| 52 Week Range | $7.87 - 16.37 |
| Market Capitalization | $326.1 M |
| Shares Outstanding | 29.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/17/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.73 |
| Beta vs. S&P 500 | N/A |
| Revenue | $705.0 K |
| Net Profit Margin | -169.03% |
| Return on Equity | -58.85% |
Analyst Ratings as of 10/14/2021
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |